Study of the Angiogenesis by PET/CT in Patients With Lymphoma

Study of the Angiogenesis Measured by PET/CT With 18F-RGD-K5 in Patients With Lymphoma : a Preliminary Study

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02490891

Acronym

RGDLymphome

Enrollment

Registered

2015-07-07

Start date

2015-11-13

Completion date

2020-10-16

Last updated

2026-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Keywords

Lymphoma, angiogenesis, PET scan

Brief summary

The aim of the study is to measure tumoral angiogenesis modifications by RGD-K5 PET/CT before and after 2 cycles of chemotherapy in patients with lymphoma and a large tumoral mass

Detailed description

After inclusion PET scans with FDG tracer and with a specific tracer of angiogenesis will be performed on patient with lymphoma. After two cycles of chemotherapy PET scans with the same tracers will be performed. Overall survival and disease free survival will be monitored during 18 months.

Interventions

DEVICERGD K5 PET scan

PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or Female * Age ≥ 18 years old * OMS ≤ 1 * Histological diagnosis of diffuse large B-cell lymphoma what ever the subtype * Presence of measurable tumor with at least a node mass superior to 3 centimeters * Stage I to IV * Inform consent signed

Exclusion criteria

* Primary cerebral lymphoma * Absence of fixing on FDG-PET exam * Pregnant , child bearing, breast feeding or without effective contraception method woman * Hypersensitivity to RGD-K5 * Hypersensitivity to FDG * Poorly controlled diabètes (glycemia ≥ 10 millimoles/liter) * Neoplastic disease (less than 2 years or in progression)

Design outcomes

Primary

Measure	Time frame	Description
Measure of angiogenesis with RGD K5 PET scan	3 months	Measure of fixation, metabolic volume and angiogenic volume with RGD K5 traver

Secondary

Measure	Time frame	Description
Measure of angiogenic volume with K5 tracer	3 months	Measure of SUV max, SUV peak, SUV mean, metabolic volume and angiogenic volume to determine angiogenesis parameters with RGD-K5 PET scansand correlation with results of anatomopathology.
Overall survival	18 months	Time between inclusion and death whatever the cause
Disease-free survival	18 months	Time between inclusion and progression or death

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026